-
1 Comment
Shandong Xinhua Pharmaceutical Company Limited is currently in a long term downtrend where the price is trading 5.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.4.
Shandong Xinhua Pharmaceutical Company Limited's total revenue rose by 13.3% to $1B since the same quarter in the previous year.
Its net income has increased by 28.4% to $79M since the same quarter in the previous year.
Finally, its free cash flow fell by 948.0% to $-64M since the same quarter in the previous year.
Based on the above factors, Shandong Xinhua Pharmaceutical Company Limited gets an overall score of 3/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| ISIN | CNE100000411 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Dividend Yield | 5.4% |
|---|---|
| Market Cap | 9B |
| PE Ratio | 7.76 |
| Target Price | 7.09 |
| Beta | -0.08 |
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. The company also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, it offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. The company was founded in 1943 and is based in Zibo, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 0719.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
